Study to assess the safety and preliminary efficacy of AZD0156 at increasing doses alone or in combination with other anti-cancer treatment in patients with advanced cancer - AToM

Inclusion Criteria

• Inclusion criteria for all parts of the study
• •Confirmation of locally advanced/metastatic cancer. Refractory or resistant to standard therapy, or have no effective standard
• •Aged at least 18 yrs
• •Reasonable health (performance status 0 or 1), stable over the previous 2 weeks
• •Females who can have children must use contraception; have a negative pregnancy test, & not be breast feeding
• •Sexually active male patients must use contraception for duration of study and for 3 months afterwards
• Inclusion criteria for Part B only
• •Tumour(s) that can be measured by CT or MRI, at least 1cm in size
• Inclusion Part B
• •Confirmation of metastatic/locally advanced cancer of specific tumour type which failed to respond to standard treatments
• Exclusion criteria for all parts of the study
• • Prior treatment with an ATM inhibitor
• • Past medical history of an inflammatory type(interstitial) lung disease or current inflammatory lung disease
• • Radiotherapy within the last 4 weeks, except palliative radiotherapy for
• bone pain relief
• •Prior treatment with drugs that may cause lung damage
• •Poor of lung function
• •History/presence of muscle weakness or abnormal blood tests relating to muscle function
• •Cancer affecting the spinal cord and/or brain unless asymptomatic and stable
• •Any evidence of severe or uncontrolled diseases, active bleeding,kidney transplant, or active infection including liver infections (hepatitis B, hepatitis C) and human immunodeficiency virus (HIV).
• •Evidence of severe lung infections
• •Receiving, or having received during the four weeks prior to starting study treatment other chemotherapy treatment for your cancer
• •Treatment with certain doses of steroids during the two weeks prior to starting study treatment
• •A known sensitivity to AZD0156 or any of its components
• •Treatment with any unapproved medicine within 28 days prior to starting study treatment
• •Receiving, or having received medications, herbal supplements and/or
• foods that significantly affect how your liver works
• •Low numbers of certain blood cells
• •If your liver and kidney aren’t working normally
• •If your heart isn’t working normally or you have a strong family history of certain heart diseases
• •Other cancers within the past 3 years, except for certain types of cervical and skin cancers
• •Sickness and vomiting, digestive diseases or previous significant bowel removal
• •Patients with uncontrolled fitting
• •Infections requiring treatment
• •Other severe and/or uncontrolled medical conditions in addition to your cancer
• •A blockage in your digestive system or severe bleeding from the stomach within 4 weeks before your take medication on the stuy
• •Patients with acute leukaemia or certain bone marrow diseases
• •Patients with a known sensitivity to olaparib or its components (Module 1), or components of FOLFIRI (Module 2)
• •Any previous treatment with drugs that work like olaparib. (Module 1 Only)